Related Experiment Videos
Effect of fenamates on prostaglandin E receptor binding
M C Rees1, R Cañete-Solér, A López Bernal
1Nuffield Department of Obstetrics and Gynaecology, John Radcliffe Hospital, Oxford.
Lancet (London, England)
|September 3, 1988
Summary
Fenamates, including sodium meclofenamate and mefenamic acid, were found to inhibit prostaglandin E2 (PGE2) receptor binding in uterine muscle tissue. This inhibition occurred in a dose-dependent manner, suggesting a potential mechanism for their effects.
Area of Science:
- Pharmacology
- Reproductive Biology
- Biochemistry
Background:
- Prostaglandin E2 (PGE2) plays a crucial role in uterine myometrial function.
- Understanding the interaction between non-steroidal anti-inflammatory drugs (NSAIDs) and prostaglandin receptors is vital for reproductive health research.
Purpose of the Study:
- To investigate the effects of fenamates on prostaglandin E receptor binding in human myometrial tissue.
- To determine the dose-dependent inhibitory potential of specific fenamates on PGE2 receptor interactions.
Main Methods:
- Myometrial tissue samples were obtained during hysterectomy procedures.
- Receptor binding assays were performed to quantify the inhibition of PGE2 binding by fenamates.
Main Results:
- Sodium meclofenamate demonstrated significant inhibition of PGE2 receptor binding.
- Mefenamic acid also inhibited PGE2 receptor binding, though with a higher effective concentration.
- The observed inhibition by both drugs was dose-dependent, with ED50 values of 20 mumol/l for sodium meclofenamate and 200 mumol/l for mefenamic acid.
Conclusions:
- Fenamates, specifically sodium meclofenamate and mefenamic acid, can inhibit prostaglandin E receptor binding in the myometrium.
- These findings suggest a potential pharmacological mechanism for fenamates impacting uterine contractility and function.